156 related articles for article (PubMed ID: 16572586)
21. Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin.
Kawada M; Inoue H; Arakawa M; Takamoto K; Masuda T; Ikeda D
Cancer Sci; 2007 Mar; 98(3):350-6. PubMed ID: 17270024
[TBL] [Abstract][Full Text] [Related]
22. The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells.
Brett A; Pandey S; Fraizer G
Mol Cancer; 2013 Jan; 12():3. PubMed ID: 23298185
[TBL] [Abstract][Full Text] [Related]
23. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
24. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia.
McCarty G; Awad O; Loeb DM
J Biol Chem; 2011 Dec; 286(51):43634-43643. PubMed ID: 22030397
[TBL] [Abstract][Full Text] [Related]
25. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.
Ngan S; Stronach EA; Photiou A; Waxman J; Ali S; Buluwela L
Oncogene; 2009 May; 28(19):2051-63. PubMed ID: 19363526
[TBL] [Abstract][Full Text] [Related]
26. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
[TBL] [Abstract][Full Text] [Related]
27. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
28. WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio.
Cunningham TJ; Palumbo I; Grosso M; Slater N; Miles CG
Blood; 2013 Jul; 122(2):188-92. PubMed ID: 23699597
[TBL] [Abstract][Full Text] [Related]
29. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
31. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells.
Steele VE; Arnold JT; Lei H; Izmirlian G; Blackman MR
Anticancer Res; 2006; 26(5A):3205-15. PubMed ID: 17094431
[TBL] [Abstract][Full Text] [Related]
33. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types.
Blok LJ; Themmen AP; Peters AH; Trapman J; Baarends WM; Hoogerbrugge JW; Grootegoed JA
Mol Cell Endocrinol; 1992 Oct; 88(1-3):153-64. PubMed ID: 1334008
[TBL] [Abstract][Full Text] [Related]
35. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
36. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
37. [Inhibitory effect of WT1 gene isoform transfection on proliferation of leukemia cell line NB4].
Shen HL; Chen ZX; Wang W; Cen JN; Hu SY; Zhao Y
Ai Zheng; 2006 Feb; 25(2):163-9. PubMed ID: 16480579
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
39. The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells.
Peng L; Wang J; Malloy PJ; Feldman D
Int J Cancer; 2008 Feb; 122(3):558-66. PubMed ID: 17918155
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
